In 2015, Novartis, Pfizer and Thermo Fisher Scientific announced a long-term partnership, with the hopes of accelerating the development and registration of several new non-small cell lung cancer (NSCLC) drugs. Over the past year, this collaboration has worked on developing and commercializing a multi-marker, universal next-generation sequencing oncology test that will serve as a companion diagnostic for NSCLC across multiple drug platforms.
Executives from Novartis, Thermo Fisher and Pfizer will be leading a panel discussion at the 8th Annual Personalized and Precision Medicine Conference, taking place October 12-13, 2016 in San Francisco, CA. For more information on the conference, visit: http://personalizedmedicinepartnerships.com.
The three executives that will lead this panel discussion are:
• Mark Stevenson, MBA, Executive VP and President of Life Science Solutions, Thermo Fisher
• Anne-Marie Martin, Ph.D., Senior VP, Global Head of Precision Medicine, Novartis
• Hakan Sakul, Ph.D., VP and Head of Diagnostics, Pfizer
As there is a growing demand for targeted therapies to replace the “one-size-fits-all” paradigm, stakeholders in the health care industry are looking to satisfy the ultimate goal of providing more personalized therapies and timely access to the appropriate clinical trials. With the continued use of next-generation sequencing, which allows for multiple genes to be simultaneously tested from a single sample, personalized and precision medicine are on the forefront of revolutionizing the health care industry.
The NGS-based companion diagnostic test for NSCLC is being developed using Thermo Fisher’s Ion PGM Dx System and Oncomine assays. Hakan Sakul commented on the collaboration, “the Thermo Fisher Scientific NGS panel is aligned with a number of our clinical development programs, providing us with an opportunity to accelerate the development of each of these potential therapies for NSCLC patients with targetable genetic alterations.”
Mark Stevenson of Thermo Fisher also commented that, “the potential to generate a paradigm shift through this agreement – from one test for one drug, to one test for multiple NSCLC therapies, represents a significant step forward in realizing the promise of precision medicine.” For more information on the collaboration, visit: http://news.thermofisher.com/press-release/life-technologies/thermo-fisher-scientific-signs-development-agreement-next-generation.